Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Bringing next-gen cannabinoid therapeutics to cancer patients
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Subscribe To Our Newsletter & Stay Updated
